Cancer is a complex group of diseases with many possible causes and refers to a large number of diseases characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue. It is one of the leading cause of death in the world but survival rates are improving for many types of cancer, thanks to improvements in cancer screening, treatment and prevention. Valeo Pharma is responsible for the commercialization of Yondelis in Canada, an important treatment option for patients with soft tissue sarcoma.
Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain. It exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.